Imatinib mesylate has become the gold standard front-line treatment of chronic myelogenous leukemia through its ability to inhibit ABL tyrosine kinase. Resistance to this inhibition may occur. We investigated the role of the K247R polymorphism in persistent sensitivity.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
role k247r
8
abl tyrosine
8
tyrosine kinase
8
k247r substitution
4
substitution abl
4
kinase domain
4
domain sensitivity
4
sensitivity imatinib
4
imatinib imatinib
4
imatinib mesylate
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!